New antibody shows promise against tough cancers in early trial
NCT ID NCT04556253
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tests a drug called AK104, which helps the immune system attack cancer cells, in people with specific types of stomach or colorectal cancer. Participants receive the drug before and after surgery to see if it can completely eliminate the tumor. The trial involves 47 patients and focuses on safety and how well the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AK104 (a bispecific antibody targeting PD-1 and CTLA-4)
What this could lead to
If successful, this could lead to a new treatment option that improves the chance of eliminating tumors before and after surgery for certain gastric and colorectal cancers.
What could go wrong
This is an early-phase trial with only 47 participants, so results may not apply to everyone. The treatment may cause side effects from immune system activation, and it's not yet proven to be better than standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MSI-H/DMMR GASTRIC CARCINOMA AND COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, 100142, China